...
首页> 外文期刊>Blood purification >Expanded Haemodialysis Therapy of Chronic Haemodialysis Patients Prevents Calcification and Apoptosis of Vascular Smooth Muscle Cells in vitro
【24h】

Expanded Haemodialysis Therapy of Chronic Haemodialysis Patients Prevents Calcification and Apoptosis of Vascular Smooth Muscle Cells in vitro

机译:慢性血液透析患者的扩增血液透析治疗可防止钙化和血管平滑肌细胞凋亡

获取原文
获取原文并翻译 | 示例

摘要

Background: Vascular calcification is a common phenomenon in patients with chronic kidney disease and strongly associated with increased cardiovascular mortality. Vascular calcification is an active process mediated in part by inflammatory processes in vascular smooth muscle cells (VSMC). These could be modified by the insufficient removal of pro-inflammatory cytokines through conventional high-flux (HF) membranes. Recent trials demonstrated a reduction of inflammation in VSMC by use of dialysis membranes with a higher and steeper cut-off. These membranes caused significant albumin loss. Therefore, the effect of high retention Onset (HRO) dialysis membranes on vascular calcification and its implications in vitro was evaluated. Methods: In the PERCI II trial, 48 chronic dialysis patients were dialyzed using HF and HRO dialyzers and serum samples were collected. Calcifying VSMC were incubated with the serum samples. Calcification was determined using alizarin red staining (AZR) and determination of alkaline phosphatase (ALP) activity. Furthermore, apoptosis was evaluated, and release of matrix Gla protein (MGP), osteopontin (OPN) and growth differentiation factor 15 (GDF-15) were measured in cell supernatants. Results: Vascular calcification in vitro was significantly reduced by 24% (ALP) and 36% (AZR) after 4 weeks of HRO dialysis and by 33% (ALP) and 48% (AZR) after 12 weeks of dialysis using HRO membranes compared to HF dialysis. Apoptosis was significantly lower in the HRO group. The concentrations of MGP and OPN were significantly elevated after incubation with HF serum compared to HRO serum and healthy controls. Similarly, GDF-15 release in the supernatant was elevated after incubation with HF serum, an effect significantly ameliorated after treatment with HRO medium. Conclusions: Expanded haemodialysis therapy reduces the pro-calcific potential of serum from dialysis patients in vitro. With a markedly reduced albumin filtration compared to high cut-off dialysis, use of the HRO dialyzers may possibly provide a treatment option for chronic dialysis patients to reduce the progression of vascular calcification. (c) 2017 S. Karger AG, Basel
机译:背景:血管钙化是慢性肾病患者的常见现象,与心血管死亡率增加强烈相关。血管钙化是一种活跃的过程,部分介导的血管平滑肌细胞(VSMC)中的炎症过程。这些可以通过常规高通量(HF)膜来修改通过常规高通量(HF)膜的促炎细胞因子不充分。最近的试验证明,通过使用具有更高和陡峭的截止的透析膜来减少VSMC中的炎症。这些膜引起了显着的白蛋白损失。因此,评估了高保留发作(Hro)透析膜对血管钙化及其体外影响的影响。方法:在PerCi II试验中,使用HF和HRO透析器透析48名慢性透析患者,并收集血清样品。将VSMC与血清样品一起孵育。使用茜素红染色(AZR)测定钙化,并测定碱性磷酸酶(ALP)活性。此外,在细胞上清液中测量凋亡,并在细胞上清液中测量基质Gla蛋白(MgP),骨桥蛋白(OPN)和生长分化因子15(GDF-15)的释放。结果:在使用Hro膜的透析12周后,在HRO透析4周后,体外血管钙化明显减少24%(ALP)和36%(AZR),并使用Hro膜在透析12周后透析后的33%(ALP)和48%(AZR) HF透析。 Hro组的细胞凋亡显着降低。与HF血清相比,与HF血清和健康对照组孵育后MGP和OPN的浓度显着升高。类似地,在用HF血清孵育后,上清液中的GDF-15释放升高,在用Hro培养基处理后显着改善的效果显着改善。结论:扩增血液透析治疗可降低透析患者的血清血清培养潜力。与高截止透析相比,用明显减少的白蛋白过滤,使用HRO透析器可能为慢性透析患者提供治疗选择,以减少血管钙化的进展。 (c)2017年S. Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号